Results 131 to 140 of about 1,591,450 (336)

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola   +12 more
wiley   +1 more source

Metastatic tumors to the stomach: clinical and endoscopic features. [PDF]

open access: yes, 2006
AIM: To evaluate the clinical and endoscopic patterns in a large series of patients with metastatic tumors in the stomach. METHODS: A total of 64 patients with gastric metastases from solid malignant tumors were retrospectively examined between 1990 and ...
DE PALMA, GIOVANNI DOMENICO   +8 more
core  

Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation

open access: yesJournal of experimental & clinical cancer research : CR, 2019
Vascular maturity and functionality are closely associated with tumor progression and chemosensitivity. The antidiabetic agent metformin has shown its ability to inhibit tumor angiogenesis in metastatic breast cancer models.
Ji-Chang Wang   +12 more
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Features of Breast Cancer Progression after Comprehensive Treatment, Prognosis of Metastatic Spread

open access: yesЛьвівський клінічний вісник
Introduction. The effectiveness of breast cancer treatment is directly related to the absence of metastatic spread after comprehensive treatment. Still, there are no clear criteria and algorithms for predicting the occurrence of this complication ...
Yu. Chuprovska   +3 more
doaj   +1 more source

Diagnosis of Metastatic Breast Cancer to an Intraabdominal Lymph Node by Endoscopic Ultrasound

open access: yesCase Reports in Gastroenterology, 2011
Breast cancer can present with metastatic disease initially or as a systemic relapse despite seemingly adequate initial treatment. We report a case of suspected metastatic breast cancer to an intraabdominal lymph node based on imaging, which was ...
Joseph T. Merrill, Young S. Oh
doaj   +1 more source

Metastatic Breast Cancer [PDF]

open access: yesMayo Clinic Proceedings, 2015
Ebtesam, Islam, J Drew, Payne
openaire   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

A review and meta analysis of health state utility values in breast cancer [PDF]

open access: yes
Background and purpose: Health-related quality of life is an important issue in the treatment of breast cancer, and health-state utilities are essential for cost-utility analysis.
Brazier, J., Peasgood, T., Ward, S.
core  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy